Michael J. Farrell, Chairman and CEO of ResMed Inc., filed a Form 4 on November 20, 2026, disclosing the vesting of performance-based restricted stock units originally granted on November 16, 2023, and a related disposition of shares for tax withholding on November 19, 2026.
Key Highlights
- Shares acquired: 48,136 shares of ResMed Common Stock were acquired on November 19, 2026, at a price of $0, representing earned performance-based restricted stock units.
- Tax withholding disposition: 28,180.245 shares were disposed of to the issuer on November 19, 2026, at $236.88 per share for tax withholding purposes.
- Performance certification: According to the filing, the compensation and leadership development committee certified on November 19, 2026, that performance metrics were met for this portion of the grant.
- Resulting direct ownership: Following the transactions, Farrell directly held 491,729 shares of ResMed Common Stock.
- Indirect ownership: The filing also reports 2,090 shares held indirectly through the Lisette and Michael Farrell Family Trust.
- Original grant date: The performance-based restricted stock units were originally granted on November 16, 2023.
ResMed CEO's 2023 Performance RSU Grant Vests After Committee Certification
ResMed Inc. (NYSE:RMD) Chairman and CEO Michael J. Farrell reported two transactions on November 19, 2026, stemming from the vesting of performance-based restricted stock units first granted on November 16, 2023. According to the filing, the company's compensation and leadership development committee certified on that date that the performance metrics were met for this portion of the grant, resulting in the acquisition of 48,136 shares at a price of $0.
Concurrent with the vesting, the filing discloses that 28,180.245 shares were disposed of to the issuer at $236.88 per share to cover tax withholding obligations arising from the vesting event. This type of transaction, coded "F" in the filing, represents a disposition to the issuer rather than an open-market sale. After both transactions, Farrell's direct beneficial ownership stood at 491,729 shares of ResMed Common Stock, according to the filing.
In addition to his direct holdings, the filing records 2,090 shares held indirectly through the Lisette and Michael Farrell Family Trust. The Form 4 was filed by one reporting person, signed by Michael J. Farrell, and submitted on November 20, 2026. No derivative securities transactions were reported in Table II of the filing.
What Was Disclosed
The filing reports the November 19, 2026, vesting of performance-based RSUs originally granted to ResMed's Chairman and CEO in November 2023, covering both the share acquisition upon committee certification and a same-day tax withholding disposition to the issuer.



Please wait processing your request...